Streetbeat News

Analyst Ratings

ARGX

William Blair analyst Myles Minter has upgraded argenx (NASDAQ:ARGX) from Market Perform to Outperform, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:20 am

INSM

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Insmed (NASDAQ:INSM) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:20 am

PTON

Baird analyst Jonathan Komp maintains a Neutral rating on Peloton Interactive (NASDAQ:PTON) and raises the price target from $4.75 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:19 am

TREE

Needham analyst Mayank Tandon has maintained a Buy rating on LendingTree and increased the price target from $67 to $78.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:17 am

MBUU

Baird analyst Craig Kennison has maintained an Outperform rating on Malibu Boats (NASDAQ:MBUU) and raised the price target from $40 to $50.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:16 am

MRUS

HC Wainwright & Co. has reiterated its Buy rating on Merus (NASDAQ:MRUS) and maintained a price target of $85, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:15 am

FOXF

Baird analyst Craig Kennison has maintained a Neutral rating on Fox Factory Holding (NASDAQ:FOXF) but has lowered the price target from $45 to $38.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:13 am

NBIX

HC Wainwright & Co. has reiterated its Buy rating on Neurocrine Biosciences, maintaining a price target of $190.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:12 am

MTW

Baird analyst Mircea Dobre has maintained a Neutral rating on Manitowoc Co (NYSE:MTW) but has lowered the price target from $13 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:11 am

LXRX

HC Wainwright & Co. has maintained a Buy rating on Lexicon Pharmaceuticals but lowered the price target from $10 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:00 am